Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
- Citation:
- Breast Cancer Res Treat vol 160 (2) 297-304
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- 40601- GSK 40603- Genentech
- Grants:
- P30 CA016672, U10 CA180821, P30 CA008748, U10 CA180818, U10 CA180882, U10 CA180867, U10 CA180838, U10 CA180888
- Corr. Author:
- Authors:
- Mehra Golshan Constance T. Cirrincione William M. Sikov Lisa A. Carey Donald A. Berry Beth Overmoyer Nora L. Henry George Somlo Elisa Port Harold J. Burstein Clifford Hudis Eric Winer David W. Ollila
- Networks:
- CA043, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003, NY021, RI005
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-40601, CALGB-40603
- Phases:
- 2, 3
- Keywords:
- Neoadjuvant therapy, HER2-positive breast cancer, Breast conserving therapy